Posted on: April 16, 2013 by Mark Boslet
Valuations are strong for venture-backed enterprise companies and Internet startups with top prospects. What about health care? Turns out 2012 was a relatively solid year there, too. Up rounds outpaced down rounds 52% to 17% over the 12 months.
Tags: Fenwick & West, Life Sciences
Posted on: July 23, 2012 by joanna
Who said there’s no liquidity in life science venture investment? Certainly not Silicon Valley Bank, which says now is a great time for making new biotech and medical device investments – and for exiting existing ones.
Tags: Life Sciences, Silicon Valley Bank
Posted on: August 12, 2011 by Mark Boslet
Several weeks ago we reported that life sciences investing rose 37% from the first to the second quarters. Here are some additional details, courtesy of PricewaterhouseCoopers: First, with venture capitalists earmarking $2.1 billion for 206 companies, the quarter was the seventh best on record since the MoneyTree Report began collecting data in 1995. The MoneyTree [...]
Tags: biotechnology, Life Sciences, Medical Devices, MoneyTree Report, PricewaterhouseCoopers
Posted on: May 16, 2011 by Mark Boslet
Covington & Burling LLP said Monday it added four partners to its life sciences team in London. The new attorneys – Paul Claydon, Natalie Diep, James Gubbins and James Halstead – will work on M&A, private equity and venture transactions. PRESS RELEASE Covington Adds Four Partners To Life Sciences Team LONDON, May 16, 2011 — [...]
Tags: Covington & Burling, Life Sciences
Posted on: May 6, 2011 by Mark Boslet
Venture investors are stoked to the max on social networking and consumer Internet companies peddling daily deals or moneymaking online services. But as hot as frothy Web deals have become, life sciences transactions remain cold. GPs know it is hard to make money on complicated early-stage drug discovery, and public market IPO investors are less [...]
Tags: biotechnology, First Quarter, Life Sciences, Medical Devices, venture capital
Posted on: December 13, 2010 by Mark Boslet
Bessemer Venture Partners has had a good 2010. A string of 12 exits brought welcome liquidity to the firm, which has offices in India, the United States and Israel. The firm saw a more than 3X return overall from the dozen deals, according to Rob Chandra, a partner in its Menlo Park, Calif.-based office. “This [...]
Tags: Bessemer Venture Partners, cleantech, Exits, India, IPOs, Life Sciences, M&A, Technology
Posted on: December 4, 2010 by Mark Boslet
The “crazy” pace of investing in Internet companies may continue next year, but cleantech fundings could lag. On the other hand, life sciences could turn in a solid performance. There is no shortage of interesting companies. This was the conclusion of a panel of VCs Thursday night at an investment forecasting event held by the [...]
Tags: 2011, Claremont Creek Ventures, cleantech, Internet, Life Sciences, Lightspeed Venture Partners, Mayfield Fund, Startups, Trinity Ventures, Venture Capital Investing